Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Ovarian Neoplasms 11Prostatic Neoplasms 8Fallopian Tube Neoplasms 4Neoplasms 3Neoplasm Metastasis 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Carcinoma, Ovarian Epithelial 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1SCLC,Extensive Stage 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Carcinosarcoma 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Castration-sensitive Prostate Cancer 1Lung Neoplasms 1Laryngeal Diseases 1Hereditary Sensory and Autonomic Neuropathies 1Hemangiosarcoma 1Head and Neck Neoplasms 1Glioblastoma 1Endometrial Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 27Cisplatin 18Carboplatin 13Cetuximab 12Radiotherapy 9Surveys and Questionnaires 8Paclitaxel 8Radiotherapy, Intensity-Modulated 6Docetaxel 6Surgical Procedures, Operative 5dostarlimab 3Therapeutics 3Standard of Care 3Radiation 3Fluorouracil 3Cyclophosphamide 3Chemoradiotherapy 3Blood Specimen Collection 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3toripalimab 2nimotuzumab 2fludarabine 2durvalumab 2atezolizumab 2abemaciclib 2X-Rays 2Taxes 2Radiosurgery 2Nivolumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × niraparib × 90 days × Clear all
NCT04313504 2026-05-07

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

University of Cincinnati

Phase 2 Completed
10 enrolled 9 charts
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡